Hamdard Dawakhana & Anr. v. Union of India Criminal Case Analysis

Factual and Procedural Background

The petitioners, Hamdard Dawakhana (a Wakf) and another entity, filed two writ petitions under Article 32 of the Constitution challenging the constitutionality of the Drug and Magic Remedies (Objectionable Advertisement) Act, 1954 (the Act) and the rules made thereunder. The petitions were consolidated because they raised identical questions of law. The petitioners alleged that, shortly after the Act came into force on 1 April 1955, regulatory authorities issued notices and orders prohibiting the advertisement and sale of several of their proprietary medicines. The Delhi Drugs Controller, on 4 December 1958, claimed the petitioners had contravened Section 3 of the Act and demanded recall of products dispatched to other states. Subsequent orders directed the cessation of sales of forty products and raised further objections to advertisements of other medicines prepared under the Unani system of medicine. The petitioners contended that the nomenclature of their drugs had long‑standing international recognition and that the Act discriminated against them, infringing Articles 19(1)(a), 19(1)(f), 19(1)(g), 14, 21, and 31 of the Constitution.

The respondents – the Union of India and various drug controllers – defended the Act as a necessary public‑health measure to curb self‑medication for serious diseases and to prevent misleading or “puffed‑up” advertisements that could endanger the community. They argued that the restriction applied only to advertisements directed at the general public and that the Act’s purpose was to protect health, not to suppress trade. The petitioners sought declarations that the Act and its rules were ultra vires, void, and violative of Part III of the Constitution, and they prayed for writs of mandamus and prohibition to set aside the regulatory orders.

Issues Before the Court

The Supreme Court was called upon to decide several intertwined constitutional questions:

Whether the prohibition on advertising drug cures under Section 3 of the Act constitutes a reasonable restriction on the freedom of speech guaranteed by Article 19(1)(a) and, if so, whether it satisfies the test of reasonableness under Article 19(2).
Whether the Act imposes an unreasonable impediment on the right to practice a profession, carry on trade or business, and acquire, hold, and dispose of property under Articles 19(1)(f) and 19(1)(g).
Whether the Act violates the equality clause of Article 14 by discriminating against manufacturers of Unani and Ayurvedic medicines.
Whether the provisions granting the executive power to add diseases to the prohibited list and to confiscate goods infringe personal liberty and property rights under Articles 21 and 31.
Whether the Act, in its true character and purpose, falls within the legislative competence of Parliament and can be sustained on the presumption of constitutionality.

Reasoning and Legal Principles

The Court began by emphasizing the doctrine of “pith and substance” as the appropriate tool for assessing the true nature of legislation when its constitutionality is challenged. Citing earlier decisions, the Court held that the substance, purpose, and mischief sought to be remedied must be examined, not merely the form of the statute. The Court reiterated that a presumption of constitutionality attaches to any law passed by Parliament, and that this presumption can be displaced only by a clear demonstration that the law transgresses a fundamental right.

In analysing the restriction on advertisement, the Court observed that the Act’s preamble expressly states its aim to control advertisements of drugs in certain disease contexts and to prohibit “magic” remedies. The dominant purpose, therefore, is public‑health protection, not the suppression of commercial speech. The Court noted that the restriction is not a blanket ban on all advertising but is limited to advertisements that claim to cure or prevent specific serious diseases, or that employ “magic” terminology. This limitation, the Court held, satisfies the reasonableness test under Article 19(2) because it is a proportionate means to achieve a legitimate objective – namely, preventing self‑medication that could jeopardise health.

Regarding Articles 19(1)(f) and (g), the Court distinguished between the freedom to carry on a trade and the power of the State to regulate that trade in the public interest. The Act does not prohibit the manufacture or sale of the medicines; it merely regulates the manner in which they may be advertised to the public. The Court therefore concluded that the Act does not amount to an unreasonable restriction on trade or profession, as the regulation is ancillary to the core activity of manufacturing and dispensing medicines, which remains lawful.

The equality challenge under Article 14 was addressed by examining whether the Act discriminates against any class of manufacturers. The Court found that the Act applies uniformly to all drug manufacturers, irrespective of the system of medicine (Allopathic, Unani, Ayurvedic, etc.). The petitioners’ claim of discrimination was based on the assertion that their traditional nomenclature was singled out, but the Court observed that the statutory language targets the content of the advertisement – i.e., claims of cure for specified diseases – rather than the source of the drug. Consequently, the Act does not violate the equality clause.

On the issue of executive power to add diseases to the prohibited list (Section 3) and to confiscate goods (Section 8), the Court examined whether such powers are “unchecked” and therefore violative of Articles 21 and 31. The Court held that the powers are exercised within a statutory framework that includes procedural safeguards, such as notice and an opportunity to be heard, and are aimed at protecting public health. Hence, they do not constitute arbitrary deprivation of liberty or property.

The Court also considered the legislative history, noting the extensive inquiries by the Chopra Committee (1930) and the Bhatia Committee (1953) into the menace of misleading drug advertisements and self‑medication. The historical backdrop demonstrated a clear mischief that Parliament intended to remedy, reinforcing the presumption of constitutionality.

Practical Significance for Criminal Litigation

The judgment clarifies the constitutional limits of regulatory statutes that contain criminal penalties, such as confiscation and prosecution for contravention of advertising prohibitions. Practitioners must appreciate that:

Regulatory restrictions on commercial speech are permissible when they are narrowly tailored to a legitimate public‑health objective and are proportionate.
The existence of a criminal sanction does not, per se, render a provision unconstitutional; the sanction must be linked to a reasonable regulatory purpose.
Procedural safeguards – notice, opportunity to be heard, and clear statutory definitions – are essential to withstand challenges under Articles 21 and 31.
Challenges based on discrimination must demonstrate differential treatment in the statute’s operative clause, not merely perceived bias against a particular industry.
The doctrine of pith and substance remains the cornerstone for assessing the true character of a statute when fundamental rights are invoked.

For litigants facing prosecution under the Act, the decision underscores the importance of examining whether the alleged advertisement falls within the prohibited categories enumerated in Section 3. If the advertisement merely informs about a product without claiming cure for a specified disease, it is likely to be outside the ambit of the prohibition. Conversely, any claim that a drug cures or prevents a disease listed in the Schedule will attract criminal liability, and the defence must focus on procedural irregularities or lack of proper notice.

In summary, the Supreme Court upheld the constitutionality of the Drug and Magic Remedies (Objectionable Advertisement) Act, 1954, affirming that the statute’s primary aim of safeguarding public health justifies the restrictions imposed on advertising. The judgment provides a robust framework for evaluating future statutes that seek to balance fundamental freedoms with regulatory imperatives, particularly in the realm of health‑related criminal law.